MPI’s DPR technology predicts which lymphoma patients (DLBCL) respond to standard treatment (R-CHO(E)P) in a blind setting

Hoersholm, Denmark; 21 February, 2015 – Medical Prognosis Institute A/S (MPI.CO) has in collaboration with the Danish University Hospital Rigshospitalet, Department of Hematology published data showing that MPI’s biomarker DRP(TM) may help identifying which patients suffering from Diffuse Large B-Cell Lymphoma (DLBCL) are likely to respond to standard treatment with combinations (R-CHO(E)P).

These results have been published in PLOS ONE, an international, peer-reviewed, open-access, online publication in which the results appear under the title ‘Development and blind clinical validation of microRNA based predictor of response to treatment with R-CHO(E)P in DLBCL’.

In a cohort of 116 de novo patients suffering from DLBCL, MPI correctly predicted who were likely to respond to the standard first line treatment with  (R-CHO(E)P) – and who were not likely to respond. Data from this investigation suggest that survival can be improved if MPI’s biomarker DRP(TM) is used to select the optimal treatment in second and third line therapy. The results require further validation in a larger cohort of relapsed DLBCL patients for the DRP’s potential clinical utility in second and third line treatment.
MPI has developed predictive miRNA profiles for DLBCL patients that can identify patients that will respond poorly to treatment with CHOP. The prediction is carried out by analyzing of small pieces of RNA, microRNA from the tumor. Research has shown that microRNA is active opening and closing the genes in cancer and therefore also sensitivity to cancer drugs.

As more than 80% of patients respond to first line treatment the high medical need and potential clinical utility lies in second and third line treatment, however, where the probability of response is smaller, and the number of available treatment options is large. Our results show that there is a potential that the predictor can assist in the selection of the optimal treatment.

Read the full publication:

“Our aim in MPI is that our DRP can support doctors selecting the most optimal treatment for the benefit of the patient. The results achieved in collaboration with leading Danish cancer doctor’s shows that we with high probability can help patients with relapsed lymph node cancer,” said Professor, Peter Buhl Jensen, M.D., CEO of MPI.

We are pleased to publish yet another clinical validation of our DRP® technology, noted Dr. Steen Knudsen, Ph.D., CSO and Co-Founder of MPI.

About MPI’s genetic response profile called Drug Response Predictor (DRP(TM))
MPI’s lead product, the DRP(TM) diagnostic platform, is a tool to develop tumor-derived gene signatures that may predict which cancer patients are highly likely responders to a given anticancer product. The DRP(TM) has been tested in 26 trials, where 22 trials showed that drug-specific DRP(TM) Biomarkers could predict which patients had a positive effect of the treatment. The DRP(TM) platform has also been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given anticancer drug.  Further to and in addition to this, individual patients’ gene patterns can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of those patients who have a high likelihood of response to the drug. The DRP(TM) platform can be used in all cancer types and has been patented for more than 60 anticancer drugs in the US.
About MPI

Medical Prognosis Institute, Inc. advances personalized medicine by partnering with cancer drug developers to apply its DRP(TM) diagnostic platform to streamline and de-risk clinical trials and drug development via biomarker optimization, patient stratification, and development of companion diagnostics.

For further information, please contact
CEO Peter Buhl Jensen, Professor, MD, Ph.D.
E-mail: [email protected]
Cell Phone: (+45) 21 60 89 22

Certified Advisor: Carsten Yde Hemme, PricewaterhouseCoopers, Strandvejen 44, 2900 Hellerup, Denmark

Sign up for press releases and receive relevant information about Allarity Therapeutics A/S